Studies have found that downregulation of IMPA2 is associated with poor outcomes in ccRCC and that miR-25-mediated IMPA2 regulation could be a potential therapeutic target [25]. This evidence concerns the gene IMPA2 and nonpapillary renal cell carcinoma.